Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Ezra Cohen

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Cohen, Ezra

Item TypeName
Concept Thyroid Neoplasms
Academic Article Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Academic Article Thyroid cancer: burden of illness and management of disease.
Academic Article Cabozantinib for the treatment of advanced medullary thyroid cancer.
Academic Article New approaches to thyroid cancer.
Academic Article Novel molecular targeted therapies for refractory thyroid cancer.
Academic Article Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Academic Article A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.
Academic Article Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
Academic Article A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Academic Article Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Academic Article Cabozantinib in progressive medullary thyroid cancer.
Academic Article Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Academic Article Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Academic Article Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Academic Article Phase 2 study of sunitinib in refractory thyroid cancer.
Academic Article Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Search Criteria
  • Thyroid Cancer